September 4, 2014 10:36 am
Outsourcing is an old concept in the healthcare industry that has recently been applied to a new area: regulatory affairs. Traditionally conducted in-house, regulatory affairs is extremely critical to a product’s success. For certain companies, this entire function can and should be outsourced in its entirety, not just for discrete projects.
September 3, 2014 10:15 am
ZMapp, the experimental drug that may have already have saved a few patients in Africa, is the most effective anti-Ebola therapy yet, according to a recent Nature paper on rhesus macaques monkeys. Read more...
August 29, 2014 8:30 am
Getting a new drug from the laboratory to the pharmacy takes years of testing, applications and information sharing. One way to shorten the drug development life cycle is to optimize content management. Read more...
August 28, 2014 9:30 am
As technological improvements have changed the way we study the genome, the amount of data associated with a single DNA sample has increased exponentially. Surprisingly, throughout this evolution the hardware and software infrastructure supporting bioanalytics has barely changed. Read more...
August 27, 2014 9:58 am
Drugs can be discovered and developed in two very different ways: at an evolutionary pace and at a revolutionary pace. The “first revolution” in biological psychiatry took place in the 1950s, and now, in the 21st century, a “second revolution” of drug development and discovery is taking place, driven by repurposing.
August 26, 2014 11:31 am
An experimental drug saved the lives of 16 of 16 monkeys with the Marburg virus, a killer near-indistinguishable from Ebola, just as symptoms broke out, said a new study. Read more...
August 25, 2014 9:49 am
The birth control pill significantly affects ovarian reserve— or the number of immature eggs in a woman’s ovaries— which can be a predictor of future fertility, according to a team in Denmark. Read more...
August 22, 2014 10:34 am
Neglected by the pharmaceutical industry before the Orphan Drug Act of 1983, rare diseases are now front and center in pharma R&D, with approximately one-third of all new medicines approved by the FDA in the past 5 years were developed for the treatment of diseases that affect fewer than 200,000 Americans. Read more...
- ‹ previous
- 2 of 2